Cost-effectiveness of preemptive skin treatment to prevent skin-toxicity caused by panitumumab in third-line therapy for KRAS wild type metastatic colorectal cancer in Japan

BACKGROUND: Clinical management of skin-toxicity associated with the use of anti-Epidermal Growth Factor Receptor (EGFR) antibodies to treat colorectal cancer maintains quality of life of patients with colorectal cancer. Results of clinical trials have recommended the efficacy of prophylactic treatm...

Descripción completa

Detalles Bibliográficos
Autores principales: Kashiwa, Munenobu, Matsushita, Ryo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8485424/
https://www.ncbi.nlm.nih.gov/pubmed/34593037
http://dx.doi.org/10.1186/s40780-021-00218-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8485424/
https://www.ncbi.nlm.nih.gov/pubmed/34593037
http://dx.doi.org/10.1186/s40780-021-00218-7

Ejemplares similares